Literature DB >> 1582973

In vitro growth of human multiple myeloma: implications for biology and therapy.

F Caligaris-Cappio1, M G Gregoretti, P Ghia, L Bergui.   

Abstract

In vitro data allow presentation of a plausible scenario for the in vivo growth, progression, and dissemination of human multiple myeloma (MM) that involves the interactions between the monoclonal B-cell clone and the bone marrow (BM) microenvironment. A large series of adhesion and extracellular matrix molecules allow trapping of circulating plasma cell precursors within the BM, and a battery of locally released cytokines promote their growth and final differentiation. Malignant B cells establish close contacts with BM stromal cells and release a host of cytokines that recruit and activate BM stromal cells and also T lymphocytes to produce other cytokines. All these cytokines might conceivably act in concert in a self-perpetuating mechanism of mutual help between malignant plasma cells and BM stromal cells to favor the progressive expansion of the malignant clone through a sort of an "avalanche effect." Also, most cytokines produced by malignant B cells, stromal cells, and activated T lymphocytes, including IL-1 beta, TNF-beta, M-CSF, IL-3, and IL-6, have osteoclast-activating properties, thus explaining why the expansion of the B-cell clone is matched by the activation and numeric increase of osteoclasts.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1582973

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

Review 1.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Cytokines involved in the progression of multiple myeloma.

Authors:  F Merico; L Bergui; M G Gregoretti; P Ghia; G Aimo; I J Lindley; F Caligaris-Cappio
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

4.  CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.

Authors:  Megan E Murray; Catherine M Gavile; Jayakumar R Nair; Chandana Koorella; Louise M Carlson; Daniela Buac; Adam Utley; Marta Chesi; P Leif Bergsagel; Lawrence H Boise; Kelvin P Lee
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

5.  A prognostic index for multiple myeloma.

Authors:  G Grignani; P G Gobbi; R Formisano; C Pieresca; G Ucci; S Brugnatelli; A Riccardi; E Ascari
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.